Clinical trials: Diabetes Type I
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes
The management goals of diabetic ketoacidosis (DKA) in the pediatric type 1 diabetes (T1DM) population are fluid and electrolyte repletion, insulin administration, and correction of acidosis in order to stabilize the patient.
- Trial name
- NCT02548494
- Testing
- Glargine, IV insulin, Electrolyte Correction
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Chattanooga-Hamilton County Hospital Authority
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
Elevations of plasma cortisol, a stress hormone, during prior episodes of low blood sugar (hypoglycemia) appear to be responsible for the deficient responses during subsequent hypoglycemia.
- Trial name
- NCT00607646
- Testing
- Dehydroepiandrosterone
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 1 Diabetes Mellitus
PRISM for Adolescents With Type 1 Diabetes
It is well-known that adolescents with type 1 diabetes are at high risk for elevated diabetes-specific distress and poor glycemic control.
- Trial name
- NCT03847194
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 2 sites in United States
- Volunteers
- 172 people
- Sponsor
- Seattle Children's Hospital
Type 1 Diabetes, Hypoglycemia
Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes
Type 1 diabetes (T1D) results from destruction of insulin producing beta cells by the body's own immune system (autoimmunity) causing an individual to lose the ability to make enough insulin to control their blood sugar levels…
- Trial name
- MUGGLE (NCT05616273)
- Testing
- Mixed Meal Tolerance Test (MMTT), Arginine Stimulation Test (AST), Home Finger Prick Sample
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- University of Exeter
Type 1 Diabetes
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
A randomized crossover trial assessing glycemic control using Reinforcement Learning trained Bolus Priming System (BPS_RL) added to the the Automated Insulin Delivery as Adaptive NETwork (AIDANET algorithm) compared to the…
- Trial name
- AIDANET+BPS_RL (NCT06728059)
- Testing
- Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sue Brown
Graft Rejection
Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
The purpose of this research study is to compare the effects of the two most commonly used anti-T cell induction agents(alemtuzumab and rabbit anti-thymocyte globulin) to prevent rejection in kidney and pancreas transplant…
- Trial name
- NCT00331162
- Testing
- Alemtuzumab, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Wake Forest University Health Sciences
Type 1 Diabetes
Screening For Social Determinants Of Health In Routine Diabetes Care
Social determinants of health (SDOH) exert a powerful influence on the everyday management of type 1 diabetes (T1D) and short and long term outcomes of T1D.
- Trial name
- SDOH (NCT07706803)
- Testing
- Social Determinants of Health (SDOH) Screening and Referral
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, Los Angeles
Type1diabetes, Hypoglycemia
Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques
The objective is to develop a novel system to predict and prevent nocturnal hypoglycemia in type 1 diabetic (T1D) patients, focused in patients with multiple daily injections (MDI) therapy.
- Trial name
- NCT03711656
- Testing
- isCGM (intermittently scanned Continuous Glucose Monitoring), Physical exercise tracker
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Clinic of Barcelona
Type 1 Diabetes
Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China
For last decade, the innovation of mobile health platform has brought new opportunities for disease management. Previous studies have shown that health management programs based on mobile platforms for patients with diabetes can…
- Trial name
- COOPERATIONS (NCT05163054)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking University Third Hospital
Diabetes Mellitus, Type 1
Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment
Efficacy of pancreatic islet transplantation at 6 months compared to an intensive insulin therapy for 2 categories of patients: patients with unstable diabetes and patients who underwent kidney transplantation.
- Trial name
- TRIMECO (NCT01148680)
- Testing
- Islet Graft
- Where
- 9 sites in France, Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Grenoble
Type 1 Diabetes Mellitus
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas.
- Trial name
- NCT00212329
- Testing
- T Cell Proliferation and Autoreactivity Assays, Cellular Immunoblot Assays, Tetramer Studies
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
Study of Offspring of Women With Type 1 Diabetes
There is an increasing trend in the society for developing obesity, type 2 diabetes and cardiovascular diseases. It is therefore important to identify the risk factors behind this tendency.
- Trial name
- EPICOM (NCT01559181)
- Where
- 3 sites in Denmark
- Volunteers
- 584 people
- Sponsor
- Odense University Hospital
Type 1 Diabetes
School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus
The purpose of this study is to determine if using school-based telemedicine for diabetes support and education in students with type 1 diabetes in grades K-8 can lead to improvement in control of diabetes and improved…
- Trial name
- NCT00566475
- Testing
- telemedicine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- State University of New York - Upstate Medical University
CTLA4 Haploinsufficiency
Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency
CTLA4 and LRBA deficiencies are rare genetic disorders, recently described, and associated with multiple clinical features. It ranges from recurrent infections, auto-immunity, and organ infiltration with lymphocytes.
- Trial name
- NCT05040256
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Montpellier
Type 1 Diabetes Mellitus
Triple Therapy in T1DM
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only…
- Trial name
- NCT03899402
- Testing
- Insulin, Semaglutide, Dapagliflozin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus, Type 1
The Link Between "Time In Range" Versus HbA1c and the Presence of Chronic COmplications in Type 1 Diabetes: a Longitudinal Study
HbA1c is currently the only metric of glucose control showing an association with chronic complications of type 1 diabetes mellitus (T1D).
- Trial name
- TIRCO (NCT05530369)
- Volunteers
- 479 people
- Sponsor
- University Hospital, Antwerp
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Advanced Solid Tumor, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
The goal of this multicenter prospective single-arm phase I/II study is to study the safety and efficacy stereotactic body radiotherapy (SBRT) combined with Cadonilimab for advanced refractory malignant solid tumors.
- Conditions
- Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor, Safety
- Trial name
- SCARCE (NCT05915481)
- Testing
- Cadonilimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.